TD-106|cas:2250288-69-6|西域试剂

TD-106,99.17%

产品编号：Bellancom-114406| CAS NO：2250288-69-6| 分子式：C₁₂H₁₁N₅O₃| 分子量：273.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-114406	￥3500.00	杭州北京（现货）
Bellancom-114406	￥5500.00	杭州北京（现货）
Bellancom-114406	￥19500.00	杭州北京（现货）
Bellancom-114406	￥29500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TD-106

产品介绍

TD-106 是一种 CRBN 蛋白调节剂，可用于降解靶蛋白。含 TD-106 的 BRD4 PROTAC 可诱导 BRD4 降解。

生物活性

TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation.

体外研究

TD-106 (0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM; 72 hours) inhibits the proliferation of NCI-H929 myeloma cell line with an CC₅₀ of 0.039 μM.
TD-106 (1, 10, 100, and 1000 nM) induces the degradation of IKZF1/3 in NCI-H929 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	NCI-H929 cells
Concentration:	72 hours
Incubation Time:	0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM
Result:	Inhibited cell proliferation with an CC₅₀ of 0.039 μM.

体内研究
(In Vivo)

TD-106 (50 mg/kg; intraperitoneally; q.d. for 14 days) possesses anti-myeloma activity in SCID mice with TMD-8 xenograft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SCID (CB-17/IcrCri-scid) mice with TMD-8 xenograft model
Dosage:	50 mg/kg
Administration:	Intraperitoneally (i.p.); q.d. for 14 days
Result:	Treatment inhibited tumor growth during this duration.

体内研究

TD-106 (50 mg/kg; intraperitoneally; q.d. for 14 days) possesses anti-myeloma activity in SCID mice with TMD-8 xenograft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SCID (CB-17/IcrCri-scid) mice with TMD-8 xenograft model
Dosage:	50 mg/kg
Administration:	Intraperitoneally (i.p.); q.d. for 14 days
Result:	Treatment inhibited tumor growth during this duration.

体内研究

TD-106 (50 mg/kg; intraperitoneally; q.d. for 14 days) possesses anti-myeloma activity in SCID mice with TMD-8 xenograft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SCID (CB-17/IcrCri-scid) mice with TMD-8 xenograft model
Dosage:	50 mg/kg
Administration:	Intraperitoneally (i.p.); q.d. for 14 days
Result:	Treatment inhibited tumor growth during this duration.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 125 mg/mL (457.46 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.6597 mL	18.2983 mL	36.5965 mL
5 mM	0.7319 mL	3.6597 mL	7.3193 mL
10 mM	0.3660 mL	1.8298 mL	3.6597 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (9.15 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.15 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.15 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.15 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明